Related references
Note: Only part of the references are listed.A Phase 1 Study of Everolimus and Sorafenib for Metastatic Clear Cell Renal Cell Carcinoma
Andrea L. Harzstark et al.
CANCER (2011)
mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways
Pat Gulhati et al.
CANCER RESEARCH (2011)
Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies
Tara C. Gangadhar et al.
CLINICAL CANCER RESEARCH (2011)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
Pat Gulhati et al.
CLINICAL CANCER RESEARCH (2009)
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
Pippa Newell et al.
JOURNAL OF HEPATOLOGY (2009)
The Pharmacology of mTOR Inhibition
David A. Guertin et al.
SCIENCE SIGNALING (2009)
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer
Lisa Simi et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
Zheng Wang et al.
CLINICAL CANCER RESEARCH (2008)
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers
Zhi Liu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
Konstantinos G. Lasithiotakis et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors
Lissandra Dal Lago et al.
ONCOLOGIST (2008)
Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis
Piotr G. Rychahou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Safety and anti-tumor activity of sorafenib (Nexavar((R))) in combination with other anti-cancer agents: a review of clinical trials
Chris H. Takimoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Oncogenic mutations of PIK3CA in human cancers
Y Samuels et al.
CELL CYCLE (2004)
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
HK Roy et al.
CARCINOGENESIS (2002)
Share Paper
